CAM
RXRX icon

Cresset Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Cresset Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$119K Sell
38,852
-385
-1% -$1.49K ﹤0.01% 1524
2025
Q4 		$160K Sell
39,237
-51
-0.1% -$253 ﹤0.01% 1527
2025
Q3 		$192K Buy
39,288
+15,125
+63% +$79.4K ﹤0.01% 1435
2025
Q2 		$122K Sell
24,163
-714
-3% -$3.51K ﹤0.01% 1351
2025
Q1 		$132K Sell
24,877
-152
-0.6% -$1.11K ﹤0.01% 1590
2024
Q4 		$169K Sell
25,029
-45,663
-65% -$307K ﹤0.01% 1587
2024
Q3 		$466K Sell
70,692
-2,660
-4% -$19.1K ﹤0.01% 1556
2024
Q2 		$550K Buy
73,352
+9,791
+15% +$85.4K ﹤0.01% 1394
2024
Q1 		$634K Buy
63,561
+11,392
+22% +$127K ﹤0.01% 1217
2023
Q4 		$514K Buy
52,169
+37,092
+246% +$264K ﹤0.01% 1222
2023
Q3 		$115K Buy
+15,077
New +$150K ﹤0.01% 1699
2023
Q1 		– Sell
-46,861
Closed -$361K – 857
2022
Q4 		$361K Hold
46,861
– – ﹤0.01% 492
2022
Q3 		$499K Hold
46,861
– – 0.01% 512
2022
Q2 		$381K Sell
46,861
-156
-0.3% -$1.04K ﹤0.01% 640
2022
Q1 		$337K Sell
47,017
-86,420
-65% -$918K ﹤0.01% 732
2021
Q4 		$2.29M Buy
+133,437
New +$2.51M 0.02% 271

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cresset Asset Management's RXRX Position: Q1 2026 in Review

Cresset Asset Management reduced its Recursion Pharmaceuticals (RXRX) stake by 0.98% in Q1 2026, selling an estimated $1.49K and leaving 38,852 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #1524.

Cresset Asset Management first reported a position in RXRX in Q4 2021 and has held it in 16 quarters since. The position peaked at $2.29M in Q4 2021. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Cresset Asset Management held 38,852 shares of Recursion Pharmaceuticals worth $119K as of Q1 2026.
  • Cresset Asset Management sold 385 Recursion Pharmaceuticals shares in Q1 2026, an estimated $1.49K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Cresset Asset Management's portfolio in Q1 2026, its #1524 holding.
  • Cresset Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 16 quarters since.
  • Cresset Asset Management's Recursion Pharmaceuticals position peaked at $2.29M in Q4 2021.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.